Skip to content

Aquestive Therapeutics, Inc.

AQST

CIK 0001398733

← back to feed
Revenue (TTM)
$45.98M
−22.6% YoY Q1 May 2026
Net Income (TTM)
−$59.98M
−89.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.59
−52.9% YoY Q1 May 2026
Gross Margin
64.8%
Q1 May 2026
Operating Margin
-101.0%
Q1 May 2026
Net Margin
-130.5%
Q1 May 2026
Free Cash Flow (TTM)
−$39.99M
Q1 May 2026
Cash
$110.73M
Q1 May 2026
Total Debt
$45M
Q1 May 2026
Shares Outstanding
125.45M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings